药效团
蛋白质精氨酸甲基转移酶5
化学
虚拟筛选
对接(动物)
IC50型
酶
药理学
体外
生物化学
甲基转移酶
甲基化
生物
医学
基因
护理部
作者
Hongrui Tao,Xue Yan,Kongkai Zhu,Hua Zhang
出处
期刊:Chemical & Pharmaceutical Bulletin
[Pharmaceutical Society of Japan]
日期:2019-03-31
卷期号:67 (4): 382-388
被引量:36
标识
DOI:10.1248/cpb.c18-00980
摘要
As an important epigenetics related enzyme, protein arginine methyltransferase 5 (PRMT5) has been confirmed as an anticancer therapeutic target in recent years. Among all the reported PRMT5 inhibitors, two small molecules (GSK-3326595 and JNJ-64619178) are currently being assessed in clinical trial. In this study, 40 PRMT5 inhibitor candidates were purchased from SPECS database supplier according to the pharmacophore and molecular docking based virtual screening results. Alpha linked immunosorbent assay (LISA) methylation assay was performed to test their inhibitory activity against PRMT5. The in vitro enzymatic assay results indicated that four compounds (2, 4, 10 and 37) showed PRMT5 inhibitory activity, while 4 and 10 displayed the most potent activity with IC50 values of 8.1 ± 1.1 and 6.5 ± 0.6 µM, respectively. The inhibitory activity results of 20 extra analogs of 4 further confirmed the potency of this scaffold. As expected, compounds 4 and 10 exhibited moderate anti-proliferative activity against mantle cell lymphoma Jeko-1 and leukemia cell MV4-11. Besides, Western blot assay results showed that 4 could reduce the H4R3me2s level in a dose-dependent manner, indicating that it could inhibit the activity of PRMT5 in cellular context. Detailed interactions between 4 and PRMT5 were characterized by binding mode analysis through molecular docking. The compounds discovered in this study will inspire medicinal chemists to further explore this series of PRMT5 inhibitors.
科研通智能强力驱动
Strongly Powered by AbleSci AI